CLINICAL_TRIALS
trial_result
· 2023-05-03
Clinical Trial Update: Anti-FGF23 (Burosumab) in Adult Patients With XLH [Phase 3]
Summary
Phase 3 trial update for burosumab in adults with X-linked Hypophosphatemia (XLH) has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Wuerzburg University Hospital | Conditions: X-linked Hypophosphatemia | Phase 3 | Status: COMPLETED